Aegerion Pharmaceuticals (AEGR) Receives Daily Media Sentiment Rating of 0.13
Media stories about Aegerion Pharmaceuticals (NASDAQ:AEGR) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aegerion Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.861046190445 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.
Receive News & Stock Ratings for Aegerion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.